Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Medulloblastoma 1Ependymoma 1

Interventions

Vincristine 9Cyclophosphamide 8Cisplatin 7Radiotherapy 6Platinum 51,2-diaminocyclohexaneplatinum II citrate 5Radiation 4Lomustine 4Filgrastim 4Etoposide 4Carboplatin 4Magnetic Resonance Spectroscopy 3Irinotecan 3Granulocyte Colony-Stimulating Factor 3sodium thiosulfate 2merphos 2Temozolomide 2Specimen Handling 2Psychiatric Rehabilitation 2Methotrexate 2sonidegib 1silmitasertib 1sargramostim 1ribociclib 1palbociclib 1omburtamab I-131 1lonafarnib 1laromustine 1emvododstat 1azurin (50-77) 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Medulloblastoma × Histamine Antagonists × Clear all
NCT04743661 2026-02-05

131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma

Pediatric Brain Tumor Consortium

Phase 2 Active not recruiting
62 enrolled
CNS

Ependymoma, Medulloblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡